PharmaEssentia company profile
Company profile
PharmaEssentia has 131 employees and is headquartered in Taipei, Taiwan.
With revenue of TWD 15.6 billion in the fiscal year ended December 2025, PharmaEssentia Corporation develops specialty pharmaceutical reagents, active pharmaceutical ingredients and new drugs, with activities in the Americas, Europe, Asia and Taiwan. Its main product, BESREMi, is used to treat polycythemia vera and essential thrombocythemia, and the company also works on treatments for adult T-cell leukemia. Its pipeline spans cancer and immunology programs, including PEG-IL-2, PD-1-IL-2v and TCR-T therapies for solid tumors.
Revenue rose 60.6% from the previous year, and net income for the same fiscal year reached TWD 5.0 billion. The company employs 131 people. Founded in 1990, it is headquartered in Taipei, Taiwan.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Taiwan
- Headquarters
- No. 3, Park Street, 115, Taipei
- Employees
- 131
- Chief executive
- Ko-Chung Lin
- Founded
- 1990
- Fiscal year
- January - December
- Listing
- 6446 · TWSE
- Currency
- TWD
- ISIN
- TW0006446008
- Website
- pharmaessentia.com
PharmaEssentia and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| PharmaEssentia6446 | Taiwan | $15.94B | 131 | 38.4% | 74.1 |
| Shionogi4507 | Japan | $16.75B | 6,223 | 31.6% | 11.2 |
| Yunnan Baiyao Group000538 | China | $15.07B | 9,286 | 11.2% | 19.4 |
| Laurus LabsLAURUSLABS | India | $14.13B | 7,059 | 24.1% | 97.8 |
| Torrent PharmaceuticalsTORNTPHARM | India | $19.25B | 18,258 | 22.2% | 79.2 |
| Zydus LifesciencesZYDUSLIFE | India | $12.92B | 29,980 | 17.2% | 28.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
